239 Users Online
Hemoglobinopathy Market Segmented By Sickle Cell Disease, Beta Thalassemia, Alpha Thalassemia Indication with Routine Red Blood Cell Count, Genetic Testing, Hemoglobin by High Performance Liquid Chromatography, Hemoglobin Isoelectric Focusing, Hemoglobin electrophoresis, Hemoglobin Solubility Test
1. Executive Summary
2. Market Taxonomy
3. Global Hemoglobinopathy Market Analysis Scenario
3.1. Pricing Analysis
3.1.1. Pricing Assumptions
3.1.2. Price Analysis per Region
3.2. Market Size (US$ Mn) and Forecast
3.2.1. Market Size and Y-o-Y Growth
3.2.2. Absolute $ Opportunity
3.3. Market Overview
3.3.1. Global Hemoglobinopathy Market Reimbursement Scenario
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Key Trends
4.6. Forecast Factors – Relevance and Impact
5. Global Hemoglobinopathy Market Analysis and Forecasts, by Indication
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis by Indication
5.3. Y-o-Y Growth Projections by Indication
5.4. Market Value Forecast, 2016–2024
5.4.1. Sickle Cell Disease
5.4.2. Beta Thalassemia
5.4.3. Alpha Thalassemia
5.5. Market Attractiveness by Indication
6. Global Hemoglobinopathy Market Analysis and Forecasts, by End User
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis by End User
6.3. Y-o-Y Growth Projections by End User
6.4. Market Value Forecast by End User, 2016–2024
6.4.1. Hospitals
6.4.2. Diagnostics Laboratories
6.4.3. Clinics
6.5. Market Attractiveness by End User
7. Global Hemoglobinopathy Market Analysis and Forecasts, by Test Type
7.1. Introduction
7.2. Basis Point Share (BPS) Analysis by Test Type
7.3. Y-o-Y Growth Projections by Test Type
7.4. Market Value Forecast by Test Type, 2016–2024
7.4.1. Routine Red Blood Cell (RBC) Count
7.4.2. Genetic Testing
7.4.3. Hemoglobin by High Performance Liquid Chromatography
7.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
7.4.5. Hemoglobin electrophoresis (Hb ELP)
7.4.6. Hemoglobin Solubility Test
7.5. Market Attractiveness by Test Type
8. Global Hemoglobinopathy Market Analysis and Forecasts, by Region
8.1. Basis Point Share (BPS) Analysis by Country
8.2. Y-o-Y Growth Projections by Country
8.3. Market Value Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. APAC
8.3.5. MEA
8.4. Market Attractiveness by Country
9. North America Hemoglobinopathy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Key Findings
9.2. Market Value Forecast by Indication, 2016–2024
9.2.1. Sickle Cell Disease
9.2.2. Beta Thalassemia
9.2.3. Alpha Thalassemia
9.3. Market Value Forecast by End User, 2016–2024
9.3.1. Hospitals
9.3.2. Diagnostics Labs
9.3.3. Clinics
9.4. Market Value Forecast by Test Type, 2016–2024
9.4.1. Routine Red Blood Cell (RBC) Count
9.4.2. Genetic Testing
9.4.3. Hemoglobin by High Performance Liquid Chromatography
9.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
9.4.5. Hemoglobin electrophoresis (Hb ELP)
9.4.6. Hemoglobin Solubility Test
9.5. Market Value Forecast by Country, 2016–2024
9.5.1. US
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. by Indication
9.6.2. by End User
9.6.3. by Test Type
9.7. Drivers and Restraints: Impact Analysis
10. Latin America Hemoglobinopathy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Key Findings
10.2. Market Value Forecast by Indication, 2016–2024
10.2.1. Sickle Cell Disease
10.2.2. Beta Thalassemia
10.2.3. Alpha Thalassemia
10.3. Market Value Forecast by End User, 2016–2024
10.3.1. Hospitals
10.3.2. Diagnostics Labs
10.3.3. Clinics
10.4. Market Value Forecast by Test Type, 2016–2024
10.4.1. Routine Red Blood Cell (RBC) Count
10.4.2. Genetic Testing
10.4.3. Hemoglobin by High Performance Liquid Chromatography
10.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
10.4.5. Hemoglobin electrophoresis (Hb ELP)
10.4.6. Hemoglobin Solubility Test
10.5. Market Value Forecast by Country, 2016–2024
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Mexico
10.5.4. Rest of Latin America
10.6. Market Attractiveness Analysis
10.6.1. by Indication
10.6.2. by End User
10.6.3. by Test Type
10.7. Drivers and Restraints: Impact Analysis
11. Europe Hemoglobinopathy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Key Findings
11.2. Market Value Forecast by Indication, 2016–2024
11.2.1. Sickle Cell Disease
11.2.2. Beta Thalassemia
11.2.3. Alpha Thalassemia
11.3. Market Value Forecast by End User, 2016–2024
11.3.1. Hospitals
11.3.2. Diagnostics Labs
11.3.3. Clinics
11.4. Market Value Forecast by Test Type, 2016–2024
11.4.1. Routine Red Blood Cell (RBC) Count
11.4.2. Genetic Testing
11.4.3. Hemoglobin by High Performance Liquid Chromatography
11.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
11.4.5. Hemoglobin electrophoresis (Hb ELP)
11.4.6. Hemoglobin Solubility Test
11.5. Market Value Forecast by Country, 2016–2024
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Poland
11.5.7. Russia
11.5.8. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. by Indication
11.6.2. by End User
11.6.3. by Test Type
11.7. Drivers and Restraints: Impact Analysis
12. APAC Hemoglobinopathy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Key Findings
12.2. Market Value Forecast by Indication, 2016–2024
12.2.1. Sickle Cell Disease
12.2.2. Beta Thalassemia
12.2.3. Alpha Thalassemia
12.3. Market Value Forecast by End User, 2016–2024
12.3.1. Hospitals
12.3.2. Diagnostics Labs
12.3.3. Clinics
12.4. Market Value Forecast by Test Type, 2016–2024
12.4.1. Routine Red Blood Cell (RBC) Count
12.4.2. Genetic Testing
12.4.3. Hemoglobin by High Performance Liquid Chromatography
12.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
12.4.5. Hemoglobin electrophoresis (Hb ELP)
12.4.6. Hemoglobin Solubility Test
12.5. Market Value Forecast by Country, 2016–2024
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia
12.5.5. Rest of APAC
12.6. Market Attractiveness Analysis
12.6.1. by Indication
12.6.2. by End User
12.6.3. by Test Type
12.7. Drivers and Restraints: Impact Analysis
13. MEA Hemoglobinopathy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Key Findings
13.2. Market Value Forecast by Indication, 2016–2024
13.2.1. Sickle Cell Disease
13.2.2. Beta Thalassemia
13.2.3. Alpha Thalassemia
13.3. Market Value Forecast by End User, 2016–2024
13.3.1. Hospitals
13.3.2. Diagnostics Labs
13.3.3. Clinics
13.4. Market Value Forecast by Test Type, 2016–2024
13.4.1. Routine Red Blood Cell (RBC) Count
13.4.2. Genetic Testing
13.4.3. Hemoglobin by High Performance Liquid Chromatography
13.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
13.4.5. Hemoglobin electrophoresis (Hb ELP)
13.4.6. Hemoglobin Solubility Test
13.5. Market Value Forecast by Country, 2016–2024
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
13.6. Market Attractiveness Analysis
13.6.1. by Indication
13.6.2. by End User
13.6.3. by Test Type
13.7. Drivers and Restraints: Impact Analysis
14. Competition Landscape
14.1. Competition Dashboard
14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
14.2.1. Abbott Diagnostics
14.2.2. Bio-Rad Laboratories, Inc.
14.2.3. Danaher Corp.
14.2.4. Mindray Medical International Ltd
14.2.5. Nexcelom Bioscience LLC.
14.2.6. Nihon Kohden Europe Ltd
14.2.7. PerkinElmer Inc.
14.2.8. Siemens Healthineers
14.2.9. Sysmex Europe GmbH
15. Assumptions and Acronyms Used
16. Research Methodology
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
List of Tables
Table 01: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 02: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 03: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 04: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Region, 2015–2024
Table 05: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 06: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 07: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 08: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 09: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 10: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 11: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 12: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 13: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 14: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 15: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 16: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 17: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 18: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 19: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 20: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 21: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 22: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 23: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 24: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
List of Figures
Figure 01: Routine Red Blood Cell (RBC) Count Test Pricing Difference (US$) By Region, 2015 A
Figure 02: Genetic Testing Pricing Difference (US$) By Region, 2015 A
Figure 03: Hemoglobin by high performance liquid chromatography (HPLC) Test Pricing Difference (US$) By Region, 2015 A
Figure 04: Hemoglobin isoelectric focusing (Hb IEF) Pricing Difference (US$) By Region, 2015 A
Figure 05: Hemoglobin electrophoresis (Hb ELP) Test Pricing Difference (US$) By Region, 2015 A
Figure 06: Hemoglobin solubility test (SST) Pricing Difference (US$) By Region, 2015 A
Figure 07: Global Hemoglobinopathy Market Value (US$ Mn) Forecast, 2016–2024
Figure 08 : Global Hemoglobinopathy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 09: Global Hemoglobinopathy Market Share and BPS Analysis (%) By Indication, 2016 & 2024
Figure 10: Global Hemoglobinopathy Y-o-Y growth (%) By Indication, 2016–2024
Figure 11: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Sickle Cell Disease Segment, 2015–2024
Figure 12: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Beta Thalassemia Segment, 2015–2024
Figure 13: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Alpha Thalassemia Segment, 2015–2024
Figure 14: Global Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 15: Global Hemoglobinopathy Market Share and BPS Analysis (%) By End User, 2016 & 2024
Figure 16: Global Hemoglobinopathy Y-o-Y growth (%) By End User, 2016–2024
Figure 17: Global Hemoglobinopathy Market Absolute $ Opportunity By Hospitals Segment, 2016–2024
Figure 18: Global Hemoglobinopathy Market Absolute $ Opportunity By Diagnostics Laboratories Segment, 2016–2024
Figure 19: Global Hemoglobinopathy Market Absolute $ Opportunity By Clinics Segment, 2016–2024
Figure 20: Global Hemoglobinopathy Market Attractiveness Analysis By End-user, 2016–2024
Figure 21: Hemoglobinopathy Market Share Analysis (%) By Test Type, 2016 & 2024
Figure 22: Global Hemoglobinopathy Y-o-Y growth (%) By Test Type, 2016–2024
Figure 23: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By RBC Count, 2015–2024
Figure 24: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Genetic Testing, 2015–2024
Figure 25: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin HPLC, 2015–2024
Figure 26: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Isoelectric Focusing, 2015–2024
Figure 27: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Electrophoresis, 2015–2024
Figure 28: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Solubility Test, 2015–2024
Figure 29: Global Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 30: Global Hemoglobinopathy Market Value (US$ Mn) and CAGR (%) By Region, 2015, 2020, and 2024
Figure 31: Global Hemoglobinopathy Market Share Analysis (%) By Region, 2016 & 2024
Figure 32: Global Hemoglobinopathy Y-o-Y growth (%) By Region, 2016–2024
Figure 33: North America Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 34: Latin America Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 35: Europe Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 36: APAC Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 37: MEA Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 38: Global Hemoglobinopathy Market Attractiveness Analysis By Region, 2016–2024
Figure 39: North America Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 40: North America Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 41: North America Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 42: North America Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 43: North America Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
Figure 44: Latin America Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 45: Latin America Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 46: Latin America Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 47: Latin America Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 48: Latin America Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
Figure 49: Europe Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 50: Europe Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 51: Europe Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 52: Europe Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 53: Europe Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
Figure 54: Asia Pacific Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 55: Asia Pacific Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 56: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 57: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 58: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
Figure 59: Middle East & Africa Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 60: Middle East & Africa Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 61: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 62: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 63: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
